Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.

CONCLUSION: Diagnostics and treatment of newly diagnosed and relapsed MM are continuously evolving. While advances in the field of (single cell) genetic analysis now allow for characterization of the disease at an unprecedented resolution, immunotherapeutic approaches and MRD testing are at the forefront of the current clinical trial landscape. PMID: 31407112 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31407112?dopt=Abstract

Source: Clin Med Res - August 11, 2019 Category: Research Authors: Baertsch MA, Lutz R, Raab MS, Weinhold N, Goldschmidt H Tags: J Cancer Res Clin Oncol Source Type: research